Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
|Articles|October 7, 2021
Medication Pearl of the Day: Tisotumab Vedotin (Tivdak) for Cervical Cancer
Author(s)Saro Arakelians, PharmD
Tisotumab vedotin, is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Advertisement
Medication Pearl of the Day: Tisotumab vedotin (Tivdak)
Indication: Tisotumab vedotin is a tissue factor (TF)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Insight:
- Dosage: For intravenous (IV) infusion only. The recommended dose of tisotumab vedotin is 2 mg/kg (up to a maximum of 200 mg) given as an IV infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.
- Dosage form: For injection, 40 mg as a lyophilized cake or powder in a single-dose vial for reconstitution.
- Adverse Events (AEs): The most common (≥25%) AEs include laboratory abnormalities, decreased hemoglobin, fatigue, decreased lymphocytes, nausea, peripheral neuropathy, alopecia, epistaxis, conjunctival AEs, hemorrhage, decreased leukocytes, increased creatinine, dry eye, increased prothrombin international normalized ratio, prolonged activated partial thromboplastin time, diarrhea, and rash.
- Drug interaction: Strong CYP3A4 Inhibitors—closely monitor for tisotumab vedotin AEs.
- Mechanism of Action: Tisotumab vedotin, a TF-directed antibody drug conjugate, is a human immunoglobulin 1 directed against cell surface TF. TF is the primary initiator of the extrinsic blood coagulation cascade.
- Manufacturer: Seagen/Genmab
Sources:
Advertisement
Related to this article
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Phase 2 DeLLphi-309 data show comparable activity in previously treated SCLC with less frequent dosing.
A retrospective study of pharmacist-supported mirogabalin treatment highlights the need for careful evidence interpretation and sustained follow-up in cancer-related neuropathic pain.
The approval gives patients aged 12 years and older a once-daily oral pellet alternative to capsules for preventing hereditary angioedema (HAE) attacks.
Ravulizumab is now the first C5 complement inhibitor approved for adults with primary IgA nephropathy at risk of disease progression.
A randomized clinical trial found that dedicated oncology pharmacist care reduced adverse drug reactions among patients with hematologic malignancies.
ENDURANCE trial finds fixed 2-year lenalidomide maintenance matches continuous therapy for standard-risk multiple myeloma survival, guiding oncology pharmacists on MM regimen toxicity.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
5